PLEKHM2

Across TCGA pan-cancer cohorts, PLEKHM2 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of PLEKHM2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where PLEKHM2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types PLEKHM2 is over-expressed in tumor, although a few such as LSCC and LUAD show the opposite, repressed pattern.

CCRCC, LSCC, and LUAD are the cancer types where PLEKHM2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PLEKHM2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Female	All	+0.326	<.001	10	view →
LSCC	All	III,IV	−0.296	<.001	9	view →
LUAD	All	III,IV	−0.215	<.001	8	view →
HNSC	All	IV	−0.183	.002	8	view →
PDAC	Male	All	+0.569	<.001	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

PLEKHM2–CCRCC

Open the CCRCC breakdown →